Albert Bourla
Albert Bourla (Greek: Άλμπερτ Μπουρλά; born October 21, 1961) is an American-Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla was chief operating officer.
Albert Bourla | |
|---|---|
Άλμπερτ Μπουρλά | |
| Born | Άλμπερτ Μπουρλά October 21, 1961 Thessaloniki, Greece |
| Education | Aristotle University of Thessaloniki (PhD, DVM) |
| Employer | Pfizer |
| Title | Chairman and CEO of Pfizer |
| Board member of |
|
| Spouse | Myriam Alchanati |
| Children | 2 |
| Honours | Golden Cross of the Order of the Redeemer |
In addition to the boards of Pfizer and the Pfizer Foundation, he is or has been on the boards of the Biotechnology Innovation Organization, Catalyst, the Partnership for New York City, and the Pharmaceutical Research and Manufacturers of America. Bourla is also a member of The Business Council and the Business Roundtable.
Bourla was motivated by an early love for animals and medicine and is credited with reshaping Pfizer to be a company focused on research and development. He is also credited with helping the development of Improvac, which eradicates boar taint, and for refocusing Pfizer's vaccine division to focus on Staphylococcus, Clostridioides difficile infection, infant diseases, and the Pfizer–BioNTech COVID-19 vaccine. He opposes government interference in pharmaceutical pricing, which he argues would hamper spending on development of new drugs.
Bourla was awarded the 2022 Genesis Prize for his leadership in the development of the Pfizer–BioNTech COVID-19 vaccine.